SCHEMBL4823774

SCHEMBL4823774

Ic1cccc(COc2ccc3ccoc3c2)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 2/20 0.65
MAOA P21397 9/20 0.50
MAOB P27338 9/20 0.50
FFAR1 O14842 1/20 0.50
PPARD Q03181 1/20 0.50
NPC1 O15118 2/20 0.47
RAB9A P51151 1/20 0.47
MEN1 O00255 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA3 P07451 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA7 P43166 1/20 0.47
MTNR1A P48039 1/20 0.47
KMT2A Q03164 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
ANO1 Q5XXA6 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7214701 0.84 MRGPRX4 (0.69) MRGPRX4MAOAMAOBFFAR1PPARD
SCHEMBL29828846 0.84 MRGPRX4 (0.69) MRGPRX4MAOAMAOBFFAR1PPARD
SCHEMBL22480680 0.79 MRGPRX4 (1.00) MRGPRX4FFAR1PPARDRAB9A
SCHEMBL14018125 0.78 MRGPRX4 (0.45) MRGPRX4MAOAFFAR1PPARDMEN1
SCHEMBL14018285 0.72 MRGPRX4 (0.52) MRGPRX4MAOAMAOBFFAR1PPARD
SCHEMBL3916599 0.72 APP (0.63) MAOAMAOBFFAR1IDO1
SCHEMBL30674750 0.72 APP (0.63) MAOAMAOBFFAR1IDO1
SCHEMBL5988383 0.72 MRGPRX4 (0.69) MRGPRX4MAOAMAOBNPC1RAB9A
SCHEMBL18006309 0.71 MRGPRX4 (0.51) MRGPRX4MAOAMAOBFFAR1PPARD
SCHEMBL9060683 0.71 APP (0.64) MAOAMAOBIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442808-B2 e.g. 3-(indan-1-yloxy)-8-(oxazolidin-2,4-dion-5-yl)-5,6,7,8-tetrahydroquinoline; with other active ingredients; agonists of G-protein coupled receptor 40 (GPR40); antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, hyperlipemia MERCK & CO., INC. (US) 2008-10-28 US disclosed
US-7442808-B2 e.g. 3-(indan-1-yloxy)-8-(oxazolidin-2,4-dion-5-yl)-5,6,7,8-tetrahydroquinoline; with other active ingredients; agonists of G-protein coupled receptor 40 (GPR40); antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, hyperlipemia MERCK & CO., INC. (US) 2008-10-28 US disclosed
US-7442808-B2 e.g. 3-(indan-1-yloxy)-8-(oxazolidin-2,4-dion-5-yl)-5,6,7,8-tetrahydroquinoline; with other active ingredients; agonists of G-protein coupled receptor 40 (GPR40); antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, hyperlipemia MERCK & CO., INC. (US) 2008-10-28 US disclosed
WO-2007136572-A2 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK & CO., INC. (US) 2007-11-29 WO disclosed
US-20070265332-A1 Antidiabetic bicyclic compounds MERCK SHARP & DOHME LLC 2007-11-15 US disclosed
US-20070265332-A1 Antidiabetic bicyclic compounds MERCK SHARP & DOHME LLC 2007-11-15 US disclosed
US-20070265332-A1 Antidiabetic bicyclic compounds MERCK SHARP & DOHME LLC 2007-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265332-A1 Antidiabetic bicyclic compounds GPR119, GPR65, FFAR4 MRGPRX4 426/4885MAOA 4143/4885MAOB 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.